What's New in Pulmonary Hypertension Clinical Research: Lessons from the Best Abstracts at the 2020 American Thoracic Society International Conference

Overview

Journal Pulm Circ

Publisher Wiley

Specialty Pulmonary Medicine

Date 2021 Sep 2

PMID 34471517

Citations 1

Authors

Andrew J Sweatt

Raju Reddy

Farbod N Rahaghi

Nadine Al-Naamani

Affiliations

Soon will be listed here.

Abstract

In this conference paper, we review the 2020 American Thoracic Society International Conference session titled, "What's New in Pulmonary Hypertension Clinical Research: Lessons from the Best Abstracts". This virtual mini-symposium took place on 21 October 2020, in lieu of the annual in-person ATS International Conference which was cancelled due to the COVID-19 pandemic. Seven clinical research abstracts were selected for presentation in the session, which encompassed five major themes: (1) standardizing diagnosis and management of pulmonary hypertension, (2) improving risk assessment in pulmonary arterial hypertension, (3) evaluating biomarkers of disease activity, (4) understanding metabolic dysregulation across the spectrum of pulmonary hypertension, and (5) advancing knowledge in chronic thromboembolic pulmonary hypertension. Focusing on these five thematic contexts, we review the current state of knowledge, summarize presented research abstracts, appraise their significance and limitations, and then discuss relevant future directions in pulmonary hypertension clinical research.

Citing Articles

Progression of pulmonary arterial hypertension: A study in model.

Cahyono A, Irwanto , Rahman M, Widjiati W Open Vet J. 2025; 14(12):3498-3504.

PMID: 39927369 PMC: 11799619. DOI: 10.5455/OVJ.2024.v14.i12.33.

Extrapulmonary manifestations of pulmonary arterial hypertension.

Singh N, Al-Naamani N, Brown M, Long G, Thenappan T, Umar S Expert Rev Respir Med. 2024; 18(3-4):189-205.

PMID: 38801029 PMC: 11713041. DOI: 10.1080/17476348.2024.2361037.

Acid ceramidase gene therapy ameliorates pulmonary arterial hypertension with right heart dysfunction.

Katz M, Hadas Y, Vincek A, Freage-Kahn L, Shtraizent N, Madjarov J Respir Res. 2023; 24(1):197.

PMID: 37568148 PMC: 10416391. DOI: 10.1186/s12931-023-02487-2.

References

Scott J, Garnett C, Kanwar M, Stockbridge N, Benza R . Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials. Am J Respir Crit Care Med. 2020; 203(6):726-736. PMC: 7958501. DOI: 10.1164/rccm.202002-0357OC. View

Hemnes A, Rothman A, Swift A, Zisman L . Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension. Pulm Circ. 2020; 10(4):2045894020957234. PMC: 7682212. DOI: 10.1177/2045894020957234. View

Galie N, Jansa P, Pulido T, Channick R, Delcroix M, Ghofrani H . SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017; 38(15):1147-1155. PMC: 5400052. DOI: 10.1093/eurheartj/ehx025. View

Lewis G, Ngo D, Hemnes A, Farrell L, Domos C, Pappagianopoulos P . Metabolic Profiling of Right Ventricular-Pulmonary Vascular Function Reveals Circulating Biomarkers of Pulmonary Hypertension. J Am Coll Cardiol. 2016; 67(2):174-189. PMC: 4962613. DOI: 10.1016/j.jacc.2015.10.072. View

Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G . Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00889-2017. View

Mey J, Hari A, Axelrod C, Fealy C, Erickson M, Kirwan J . Lipids and ketones dominate metabolism at the expense of glucose control in pulmonary arterial hypertension: a hyperglycaemic clamp and metabolomics study. Eur Respir J. 2020; 55(4). PMC: 7263739. DOI: 10.1183/13993003.01700-2019. View

Chang K, Duval S, Badesch D, Bull T, Chakinala M, De Marco T . Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. J Am Heart Assoc. 2022; 11(9):e024969. PMC: 9238604. DOI: 10.1161/JAHA.121.024969. View

Tao Z, Loo S, Su L, Tan S, Tee G, Gan S . Angiopoietin-1 enhanced myocyte mitosis, engraftment, and the reparability of hiPSC-CMs for treatment of myocardial infarction. Cardiovasc Res. 2020; 117(6):1578-1591. DOI: 10.1093/cvr/cvaa215. View

Brittain E, Niswender K, Agrawal V, Chen X, Fan R, Pugh M . Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension. J Am Heart Assoc. 2020; 9(22):e018349. PMC: 7763730. DOI: 10.1161/JAHA.120.018349. View

10.

Lorenzen J, Nickel N, Kramer R, Golpon H, Westerkamp V, Olsson K . Osteopontin in patients with idiopathic pulmonary hypertension. Chest. 2010; 139(5):1010-1017. DOI: 10.1378/chest.10-1146. View

11.

Rhodes C, Ghataorhe P, Wharton J, Rue-Albrecht K, Hadinnapola C, Watson G . Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. Circulation. 2016; 135(5):460-475. PMC: 5287439. DOI: 10.1161/CIRCULATIONAHA.116.024602. View

12.

Jamieson S, Kapelanski D, Sakakibara N, Manecke G, Thistlethwaite P, Kerr K . Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg. 2003; 76(5):1457-62. DOI: 10.1016/s0003-4975(03)00828-2. View

13.

Nicolini G, Forini F, Kusmic C, Iervasi G, Balzan S . Angiopoietin 2 signal complexity in cardiovascular disease and cancer. Life Sci. 2019; 239:117080. DOI: 10.1016/j.lfs.2019.117080. View

14.

BELL Jr A, Shimomura S, TAYLOR Jr J, FITZPATRICK H . Detection of pulmonary lesions in patients with congenital and acquired heart disease by wedge pulmonary arteriography. Prog Cardiovasc Dis. 1959; 2:64-75. DOI: 10.1016/s0033-0620(59)80011-6. View

15.

Karakelides H, Irving B, Short K, OBrien P, Nair K . Age, obesity, and sex effects on insulin sensitivity and skeletal muscle mitochondrial function. Diabetes. 2009; 59(1):89-97. PMC: 2797949. DOI: 10.2337/db09-0591. View

16.

Kiely D, Levin D, Hassoun P, Ivy D, Jone P, Bwika J . EXPRESS: Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI). Pulm Circ. 2019; :2045894019841990. PMC: 6732869. DOI: 10.1177/2045894019841990. View

17.

Diller G, Kempny A, Babu-Narayan S, Henrichs M, Brida M, Uebing A . Machine learning algorithms estimating prognosis and guiding therapy in adult congenital heart disease: data from a single tertiary centre including 10 019 patients. Eur Heart J. 2019; 40(13):1069-1077. PMC: 6441851. DOI: 10.1093/eurheartj/ehy915. View

18.

van Walraven C, Austin P, Jennings A, Quan H, Forster A . A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009; 47(6):626-33. DOI: 10.1097/MLR.0b013e31819432e5. View

19.

Lukasz A, Beutel G, Kumpers P, Denecke A, Westhoff-Bleck M, Schieffer B . Angiopoietin-2 in adults with congenital heart disease and heart failure. PLoS One. 2013; 8(6):e66861. PMC: 3691231. DOI: 10.1371/journal.pone.0066861. View

20.

Sitbon O, Channick R, Chin K, Frey A, Gaine S, Galie N . Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26):2522-33. DOI: 10.1056/NEJMoa1503184. View